Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0P6TX
|
||||
| Former ID |
DNC006105
|
||||
| Drug Name |
1-(3-benzyloxy-pyridin-2-yl)-3-phenyl-urea
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [527996] | ||
| Formula |
C19H17N3O2
|
||||
| Canonical SMILES |
C1=CC=C(C=C1)COC2=C(N=CC=C2)NC(=O)NC3=CC=CC=C3
|
||||
| InChI |
1S/C19H17N3O2/c23-19(21-16-10-5-2-6-11-16)22-18-17(12-7-13-20-18)24-14-15-8-3-1-4-9-15/h1-13H,14H2,(H2,20,21,22,23)
|
||||
| InChIKey |
PFMMAQSZJDBKOE-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Peptidyl-prolyl cis-trans isomerase A | Target Info | Inhibitor | [527996] | |
| Reactome | Platelet degranulation | ||||
| Uncoating of the HIV Virion | |||||
| Budding and maturation of HIV virion | |||||
| Integration of provirus | |||||
| Early Phase of HIV Life Cycle | |||||
| Minus-strand DNA synthesis | |||||
| Plus-strand DNA synthesis | |||||
| Binding and entry of HIV virion | |||||
| Assembly Of The HIV Virion | |||||
| APOBEC3G mediated resistance to HIV-1 infection | |||||
| Basigin interactions | |||||
| References | |||||